-
JBCRG-11CPA TR
Translational research for JBCRG-11CPA ("Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy.")
- Status
-
No Longer Recruiting
- Objectives
-
Identification of a molecular marker to predict the therapeutic effect and marker for "Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy."
- Subjects
-
Among the patients who participated in the "Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + Low-Dose CPA Combination Therapy for Nonresponders to EXE Therapy." those who submitted tumor tissues and blood samples for this study.
1)Paraffin block 2)Frozen section 3)Serum 4)Blood sample for CEC
- Endpoints
-
1)Analysis of paraffin embedded samples, before, after and during treatment. 2)Analysis and immunostaining of frozen section, Expression analysis of mRNA. 3)Analysis of blood samples.
- Trial Period
-
2010.Oct～2024.Sep（Entry period：4years, Follow up period ：10years from last entry）
- Lead Principal Investigator
-
Masakazu Toi(Kyoto University), Hironobu Sasano(Tohoku University), Takayuki Ueno(Kyorin University)
- Target Sample Size
-
Patients who agreed to enter JBCRG-11CPA TR
- Regimen
-
- Source of Funding
-
Japan Breast Cancer Reserch Group
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
- jRCT
-
- Memo
-
- COI Disclosure
-
